

Name | Size/Type | Description | Date |
---|---|---|---|
Dabrafenib & Trametinib consent | 114KB PDF | Dabrafenib & Trametinib consent | 05 Oct 2020 |
Dacarbazine for melanoma consent | 146KB PDF | Dacarbazine for melanoma consent | 16 May 2021 |
Dactinomycin consent | 111KB PDF | Dactinomycin consent | 04 May 2021 |
Denosumab consent | 111KB PDF | Denosumab consent | 12 Nov 2020 |
Docetaxel & Carboplatin consent | 114KB PDF | Docetaxel & Carboplatin consent | 09 Jul 2020 |
Docetaxel & Cyclophosphamide consent | 113KB PDF | Docetaxel & Cyclophosphamide consent | 21 Apr 2020 |
Docetaxel & Nintedanib consent | 114KB PDF | Docetaxel & Nintedanib consent | 21 Apr 2020 |
Docetaxel consent | 113KB PDF | Docetaxel consent | 21 Apr 2020 |
Docetaxel, Pertuzumab & Trastuzumab (MBC) consent | 116KB PDF | docetaxel pertuzumab trastuzumab consent | 26 Feb 2021 |
Dostarlimab consent | 113KB PDF | Dostarlimab consent | 29 Jul 2022 |
Doxorubicin consent | 113KB PDF | Doxorubicin consent | 21 Apr 2020 |
Durvalumab consent | 86KB PDF | Durvalumab consent | 30 Jan 2025 |
All consent forms on this website are for the use of St Luke’s Cancer Alliance staff in respect of St Luke’s Cancer Alliance patients only.
For those who do not work within St Luke’s Cancer Alliance:
Use of this site and any information on it is at your own risk. We do not accept responsibility for the use of any information that may be set out on the website. You assume full responsibility for the use of the information. You may wish to take your own legal advice before using any of the consent forms.
Please note that the consent forms below are not tumour-specific; one consent form may be used to consent patients for more than one St Luke’s Alliance chemotherapy protocol which uses the same combination of chemotherapy.
These consent forms should act as an aide-memoire to health professionals and patients, by providing a check-list of the kind of information which patients should be offered, and by enabling the patient to have a written record of the main points discussed.
The relevant Macmillan leaflet(s) should also be provided to each patient before consent. In no way should written information given to the patient be regarded as a substitute for face-to-face discussions with the patient.
These consent forms are for solid tumour chemotherapy only, and are NOT to be used for chemo-radiotherapy regimens.